DailyStocks Stock Article Search

https://seekingalpha.com/article/4677790-heron-therapeutics-inc-hrtx-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Mar 12, 2024 - Heron Therapeutics, Inc. (NASDAQ:NASDAQ:HRTX) Q4 2023 Earnings Conference Call March 12, 2024 4:30 PM ETCompany ParticipantsCraig Collard – Chief Executive... 0

https://www.zacks.com/stock/news/2239599/compared-to-estimates-heron-therapeutics-hrtx-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2239599 Mar 12, 2024 - Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2237603/oncternal-therapeutics-onct-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2237603 Mar 07, 2024 - Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -0.65% and 74.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2235633/nektar-therapeutics-nktr-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2235633 Mar 04, 2024 - Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2233401/jazz-pharmaceuticals-jazz-q4-earnings-lag-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233401 Feb 28, 2024 - Jazz (JAZZ) delivered earnings and revenue surprises of -4.56% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2221985/all-you-need-to-know-about-heron-therapeutics-hrtx-rating-upgrade-to-strong-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2221985 Feb 06, 2024 - Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). 0